Betamethasone valerate foam - Foamix

Drug Profile

Betamethasone valerate foam - Foamix

Alternative Names: Betamethasone 0.12% emollient foam - Foamix; BetMetFoam Emollient; BetMetFoam Oily; BetMetFoam Waterless

Latest Information Update: 20 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Foamix
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Fluorinated steroids; Glucocorticoids; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Atopic dermatitis; Psoriasis

Highest Development Phases

  • Phase II Atopic dermatitis; Psoriasis

Most Recent Events

  • 20 Aug 2015 Phase-II development is ongoing for atopic dermatitis and psoriasis in Israel
  • 02 May 2013 Phase-II development is ongoing in Israel
  • 31 Mar 2011 Phase-II development is ongoing in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top